BMS at the 64th ASH Annual Meeting & Exposition
Delivering transformative research across major hematologic diseases
INTENDED FOR U.S. SCIENTIFIC AUDIENCES ONLY.
Our data at the 2022 American Society of Hematology (ASH) Annual Meeting reinforce our commitment to transforming the lives of patients with blood cancers and disorders through science. We are excited to share data and research across a broad range of hematologic diseases, including multiple myeloma, lymphomas, leukemias and other blood disorders.
Hear from Samit Hirawat, MD, executive vice president and chief medical officer, Global Drug Development, and Kristen Hege, MD, senior vice president, Early Clinical Development, about how our heritage and leadership in hematology uniquely position us to treat patients living with multiple myeloma and other hematologic diseases, now and in the future.
Discover multiple myeloma resources for patients, caregivers and HCPs.
Our Data at ASH
Read more about our key data being presented at ASH 2022.
- Preview our ASH data across a range of blood cancers and disorders >
- Access the virtual program here >
- Learn more about BMS' presence at ASH >
- Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio >
Advancing Innovative Research Platforms
Over the last several decades, our innovative medicines have improved how blood cancer is treated, making long-term survival a possibility for more patients. But there is more work to do, and we strive to help more patients with our medicines, scientific discovery and investigational research. This year at ASH, we'll be presenting some of our most exciting data and research. Learn more about the approach that underpins this innovation.
Our Leadership in Cell Therapy
Bristol Myers Squibb has a legacy of pioneering practice-changing therapies for people with cancer. Building on this heritage of innovation, our industry-leading team is pursuing a comprehensive strategy to unlock the full potential of cell therapy, a highly personalized type of immunotherapy that continues to transform the cancer treatment landscape.
Our Commitment to Hematological Cancers
At Bristol Myers Squibb, we’re centered on delivering better outcomes for all patients with blood cancers and across many hematologic conditions. However, hundreds of thousands of patients still have unmet needs for their disease. For these patients, we keep innovating. Learn more here:
Severyne lives with a chronic cancer. While she knows her cancer may return, she chooses hope over fear. She looks to the positive side of her journey — meeting new people, promising treatment options and cherishing the sweet moments in her life. Hear what keeps her hopeful as she navigates life with this disease.
At Bristol Myers Squibb, we are driven to understand human biology and the complexities of cancer in order to advance the next generation of therapies. Our comprehensive pipeline, spanning multiple approaches across platforms and modalities, enables us to fulfill our vision of transforming patients’ lives through science.
Disease State and Treatment Infographics
Download infographic resources on different types of blood cancers and therapies.